Thermo Fisher Scientific Inc.

NYSE:TMO   4:00:00 PM EDT
540.03
-11.22 (-2.04%)
5:05:05 PM EDT: $539.53 -0.50 (-0.09%)
Products

Thermo Fisher Scientific Announces FDA Approval Of Oncomine DX Target Test To Aid In Therapy Selection For Patients With Ret Mutations/Fusions In Thyroid Cancers

Published: 09/27/2022 20:39 GMT
Thermo Fisher Scientific Inc. (TMO) - Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test As the First Ngs-based Companion Diagnostic to Aid in Therapy Selection for Patients With Ret Mutations/fusions in Thyroid Cancers.